Tilvestamab, an anti-AXL mAb, demonstrated a tolerable safety profile with limited preliminary antitumor activity in a phase 1 clinical trial of patients with relapsed, platinum-resistant high-grade serous ovarian cancer (48). This evidence concerns the gene AXL and ovarian serous adenocarcinoma.